

WEST Search History

DATE: Monday, April 24, 2006

Hide?	Set Name	Query	Hit Count
		<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=OR</i>	
<input type="checkbox"/>	L3	L2 same (interferon or IFN)	29
<input type="checkbox"/>	L2	L1 same blood	504
<input type="checkbox"/>	L1	(oligoadenylate adj sythetase) or OAS	817326

END OF SEARCH HISTORY

AB CpG oligonucleotides (CpG-ODNs)
affect innate and adaptive immune

responses, including antigen presentation,
costimulatory molecule
expression, dendritic cell maturation, and
induction of cytokines
enhancing antibody-dependent cell-mediated
cytotoxicity (ADCC). We

conducted a phase 1 study evaluating 4 dose
levels of a CpG-ODN (11018

ISS) with rituximab in 20 patients with
relapsed non-Hodgkin lymphoma

(NHL). Patients received CpG once a week
for 4 weeks beginning after the
second of 4 rituximab infusions. Adverse
events were minimal.

Quantitative polymerase chain reaction (PCR)
measurements of a panel of

genes inducible by CpG-ODN and interferons
were performed on blood samples

collected before and 24 hours after CpG. A
dose-related increase was

measured in the expression of several
interferon-inducible genes after CpG

and correlated with serum levels of 2'-5'
oligoadenylate synthetase (OAS),

a validated interferon response marker.

Genes induced selectively by
interferon-gamma (IFN-gamma) were not
significantly induced by CpG. In

conclusion, we have defined a set of gene
expression markers that provide
a sensitive measure of biologic responses of
patients to CpG therapy in a

dose-related manner. Moreover, all the genes
significantly induced by

this CpG are regulated by type 1 interferons.
providing insight into the

dominant immune mechanisms in humans.

CpG treatment resulted in no

significant toxicity, providing ration-ale for
further testing of this

exciting combination immunotherapy
approach to NHL. Copyright 2005 by The
American Society of Hematology.

L4 ANSWER 5 OF 9 USPATFULL on STN
ACCESSION NUMBER: 2004:177784

USPATFULL

TITLE: Branched immunomodulatory
compounds and methods of
using the same

INVENTOR(S): Fearon, Karen L.,
Lafayette, CA, UNITED STATES

PATENT ASSIGNEE(S): Dynavax
Technologies Corporation (U.S. corporation)

NUMBER KIND DATE

PATENT INFORMATION: US 2004136948

A1 20040715

APPLICATION INFO.: US 2003-739518

A1 20031217 (10)

NUMBER DATE

PRIORITY INFORMATION: US 2002-

436406P 20021223 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: MORRISON &
FOERSTER LLP, 755 PAGE MILL RD, PALO
ALTO,

CA, 94304-1018

NUMBER OF CLAIMS: 20

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 8 Drawing

Page(s)

LINE COUNT: 4780

CAS INDEXING IS AVAILABLE FOR THIS
PATENT.

AB The invention provides
immunomodulatory compounds and methods for
immunomodulation of cells and individuals
using the immunomodulatory
compounds.

CAS INDEXING IS AVAILABLE FOR THIS
PATENT.

L4 ANSWER 6 OF 9 USPATFULL on STN

ACCESSION NUMBER: 2004:172513

USPATFULL

TITLE: Chimeric immunomodulatory
compounds and methods of
using the same-IV

INVENTOR(S): Fearon, Karen L.,
Lafayette, CA, UNITED STATES

Dina, Dino, Oakland, CA,

UNITED STATES

Tuck, Stephen F., Oakland, CA,
UNITED STATES

NUMBER KIND DATE

PATENT INFORMATION: US 2004132677

A1 20040708

APPLICATION INFO.: US 2003-623371

A1 20030718 (10)

RELATED APPLN. INFO.: Continuation-in-
part of Ser. No. US 2002-328578, filed

on 23 Dec 2002, PENDING
Continuation-in-part of Ser.
No. US 2002-176883, filed on 21
Jun 2002, PENDING
Continuation-in-part of Ser. No.
US 2002-177826, filed
on 21 Jun 2002, PENDING

NUMBER	DATE

PRIORITY INFORMATION: US 2001-299883P 20010621 (60)	
US 2002-375253P	20020423
(60)	
US 2002-375253P	20020423
(60)	
US 2001-299883P	20010621
(60)	
DOCUMENT TYPE: Utility	
FILE SEGMENT: APPLICATION	
LEGAL REPRESENTATIVE: MORRISON & FOERSTER LLP, 755 PAGE MILL RD, PALO ALTO,	

CA, 94304-1018
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 21 Drawing
Page(s)
LINE COUNT: 8072
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides immunomodulatory compounds and methods for immunomodulation of individuals using the immunomodulatory compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 7 OF 9 USPATFULL on STN
ACCESSION NUMBER: 2004:7759
USPATFULL
TITLE: Method for preparation of large volume batches of poly-ICLC with increased biological potency; therapeutic, clinical and veterinary uses thereof
INVENTOR(S): Salazar, Andres, Washington, DC, UNITED STATES
PATENT ASSIGNEE(S): ONCOVIR, INC. (U.S. corporation)

NUMBER	KIND	DATE

PATENT INFORMATION: US 2004005998
A1 20040108
APPLICATION INFO.: US 2003-611614
A1 20030701 (10)

NUMBER	DATE

PRIORITY INFORMATION: US 2002-393713P 20020703 (60)	
DOCUMENT TYPE: Utility	
FILE SEGMENT: APPLICATION	
LEGAL REPRESENTATIVE: Max Stul Oppenheimer, P.O. Box 50, Stevenson, MD, 21153	
NUMBER OF CLAIMS:	10
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	5 Drawing
Page(s)	
LINE COUNT:	846
CAS INDEXING IS AVAILABLE FOR THIS PATENT.	
AB Method for producing large lots of final sterile Poly-ICLC suitable for clinical use with reduced toxicity at effective dose levels, and method for using Poly-ICLC to regulate genes, and method for using Poly-ICLC to treat certain human and veterinary infectious, neoplastic and autoimmune disorders.	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 8 OF 9 USPATFULL on STN
ACCESSION NUMBER: 2003:319267
USPATFULL
TITLE: Chimeric immunomodulatory compounds and methods of using the same - III
INVENTOR(S): Fearon, Karen L., Lafayette, CA, UNITED STATES
Dina, Dino, Oakland, CA, UNITED STATES
Tuck, Stephen F., Oakland, CA, UNITED STATES

NUMBER	KIND	DATE

PATENT INFORMATION: US 2003225016		
A1 20031204		
APPLICATION INFO.: US 2002-328578		
A1 20021223 (10)		
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2002-176883, filed		

on 21 Jun 2002, PENDING
Continuation-in-part of Ser.
No. US 2002-177826, filed on 21
Jun 2002, PENDING

NUMBER	DATE
PRIORITY INFORMATION: US 2001-299883P 20010621 (60)	
US 2002-375253P	20020423
(60)	
US 2001-299883P	20010621
(60)	
US 2002-375253P	20020423
(60)	
DOCUMENT TYPE: Utility	
FILE SEGMENT: APPLICATION	
LEGAL REPRESENTATIVE: Randolph T. Apple, Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, CA, 94304-1018	
NUMBER OF CLAIMS: 33	
EXEMPLARY CLAIM: 1	
NUMBER OF DRAWINGS: 19 Drawing Page(s)	
LINE COUNT: 7262	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.	
AB The invention provides immunomodulatory compounds and methods for immunomodulation of individuals using the immunomodulatory compounds.	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.	
L4 ANSWER 9 OF 9 MEDLINE on STN	
ACCESSION NUMBER: 90232662	
MEDLINE	
DOCUMENT NUMBER: PubMed ID: 1691881	
TITLE: [Interferon, oligoadenylate synthetase and oligoadenine nucleotide--a cell biological triad]. Interferon, oligoadenylatsyntetase og oligoadeninnukleotid--en cellebiologisk triade.	
AUTHOR: Bonnevie-Nielsen V	
CORPORATE SOURCE: Odense Sygehus, Klinisk Kemisk Afdeling.	
SOURCE: Ugeskrift for laeger, (1990 Apr 16) Vol. 152, No. 16, pp. 1140-3. Ref: 30	
Journal code: 0141730. ISSN: 0041-5782.	
PUB. COUNTRY: Denmark	

DOCUMENT TYPE: Journal; Article;
(JOURNAL ARTICLE)
General Review; (REVIEW)
LANGUAGE: Danish
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199005
ENTRY DATE: Entered STN: 6 Jul 1990
Last Updated on STN: 29 Jan 1996
Entered Medline: 31 May 1990
AB In sensitive cells interferon (IFN) induces many genes leading to an increased production of several different proteins. One of these gene products is the enzyme oligoadenylatesynthetase (OAS). The main effect of this IFN induced enzyme activation is the production of oligonucleotides (2-5A) from cellular ATP. The 2-5A activates an endogeneous ribonuclease (RNase), which cleaves rRNA and mRNA. The sum of these effects is degradation of cellular and viral RNA, resulting in reduced protein synthesis. Taken together, IFN, OAS and 2-5A exist as a part of immune defence system primarily directed against virus infections. Furthermore, it is possible that this system under normal, physiological conditions regulates the growth of somatic cells. The virus inhibiting effect of IFN has been useful in the treatment of viral infections and certain types of cancer. Probably, the IFN dependent enzyme systems will achieve a greater therapeutic significance in the future.

=> log y
COST IN U.S. DOLLARS
SINCE FILE TOTAL ENTRY
SESSION
FULL ESTIMATED COST
38.98 43.77

STN INTERNATIONAL LOGOFF AT 12:01:11
ON 24 APR 2006

FULL ESTIMATED COST
4.58 4.79

FILE 'MEDLINE' ENTERED AT 11:54:44 ON
24 APR 2006

FILE 'CAPLUS' ENTERED AT 11:54:44 ON 24
APR 2006

USE IS SUBJECT TO THE TERMS OF YOUR
STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR
DETAILS.

COPYRIGHT (C) 2006 AMERICAN
CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 11:54:44 ON
24 APR 2006

Copyright (c) 2006 Elsevier B.V. All rights
reserved.

FILE 'BIOSIS' ENTERED AT 11:54:44 ON 24
APR 2006

Copyright (c) 2006 The Thomson Corporation

FILE 'USPATFULL' ENTERED AT 11:54:44
ON 24 APR 2006

CA INDEXING COPYRIGHT (C) 2006
AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS
SINCE FILE TOTAL

ENTRY

SESSION
FULL ESTIMATED COST
4.58 9.37

=> s OAs or oligoadenylate (W) sythetase
L1 3600 OAS OR OLIGOADENYLATE
(W) SYTHETASE

=> s IFN or interferon
L2 491466 IFN OR INTERFERON

=> s l1 (A) l2
L3 12 L1 (A) L2

=> duplicate remove l3
DUPLICATE PREFERENCE IS 'MEDLINE,
CAPLUS, EMBASE, BIOSIS, USPATFULL'
KEEP DUPLICATES FROM MORE THAN
ONE FILE? Y/(N):n
PROCESSING COMPLETED FOR L3
L4 9 DUPLICATE REMOVE L3 (3
DUPLICATES REMOVED)

=> d l1- ibib, abs

'L6-' IS NOT A VALID FORMAT

In a multifile environment, a format can only be
used if it is valid

in at least one of the files. Refer to file specific
help messages

or the STNGUIDE file for information on
formats available in

individual files.

REENTER DISPLAY FORMAT FOR ALL
FILES (FILEDEFAULT):d l4 1- abs ibib

'D' IS NOT A VALID FORMAT

In a multifile environment, a format can only be
used if it is valid

in at least one of the files. Refer to file specific
help messages

or the STNGUIDE file for information on
formats available in

individual files.

REENTER DISPLAY FORMAT FOR ALL
FILES (FILEDEFAULT):l4 1- ibib,abs

'L19' IS NOT A VALID FORMAT

'1-' IS NOT A VALID FORMAT

In a multifile environment, a format can only be
used if it is valid

in at least one of the files. Refer to file specific
help messages

or the STNGUIDE file for information on
formats available in

individual files.

REENTER DISPLAY FORMAT FOR ALL
FILES (FILEDEFAULT):ibib,abs

L4 ANSWER 1 OF 9 USPATFULL on STN
ACCESSION NUMBER: 2006:68033

USPATFULL

TITLE: Immunostimulatory sequence
oligonucleotides and methods

of using the same

INVENTOR(S): Dina, Dino, Oakland,
CA, UNITED STATES

Fearon, Karen L., Lafayette, CA,
UNITED STATES

Marshall, Jason, Oakland, CA,
UNITED STATES

NUMBER KIND DATE

PATENT INFORMATION: US 2006058254

A1 20060316

APPLICATION INFO.: US 2003-741720

A1 20031218 (10)

NUMBER DATE

PRIORITY INFORMATION: US 2002-
436122P 20021223 (60)

PATENT INFORMATION: US 2006058254
A1 20060316
APPLICATION INFO.: US 2003-741720
A1 20031218 (10)

NUMBER DATE

PRIORITY INFORMATION: US 2002-

436122P 20021223 (60)

US 2003-447885P 20030213

(60)

US 2003-467546P 20030501

(60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: MORRISON &
FOERSTER LLP, 755 PAGE MILL RD, PALO
ALTO,

CA, 94304-1018, US

NUMBER OF CLAIMS: 35

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 2 Drawing
Page(s)

LINE COUNT: 5755

CAS INDEXING IS AVAILABLE FOR THIS
PATENT.

AB The invention provides
immunomodulatory polynucleotides and
methods for
immunomodulation of individuals using the
immunomodulatory
polynucleotides.

CAS INDEXING IS AVAILABLE FOR THIS
PATENT.

L4 ANSWER 2 OF 9 USPATFULL on STN
ACCESSION NUMBER: 2005:286873
USPATFULL

TITLE: Molecular targets of cancer
and aging

INVENTOR(S): Tainsky, Michael A.,
West Bloomfield, MI, UNITED STATES

Draghici, Sorin, Troy, MI,

UNITED STATES

Studitskaia, Olga I., Edison, NJ,

UNITED STATES

NUMBER KIND DATE

PATENT INFORMATION: US 2005250137

A1 20051110

APPLICATION INFO.: US 2005-85440

A1 20050321 (11)

RELATED APPLN. INFO.: Continuation-in-
part of Ser. No. WO 2003-US29624, filed

on 22 Sep 2003, PENDING

NUMBER DATE

PRIORITY INFORMATION: US 2002-

412228P 20020920 (60)

US 2003-478548P 20030613

(60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: Amy E.
Rinaldo, KOHN & ASSOCIATES, PLLC, Suite
410,

30500 Northwestern Highway,

Farmington Hills, MI,

48334, US

NUMBER OF CLAIMS: 20

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 14 Drawing
Page(s)

LINE COUNT: 5555

CAS INDEXING IS AVAILABLE FOR THIS
PATENT.

AB A diagnostic tool for use in diagnosing
diseases, the tool is a detector
for detecting a presence of an array of
markers being used to determine
gene expression changes that are related to
cellular immortalization,
the presence of the markers being indicative
of a specific disease and
the markers and treatments found by the
tool. A tool for interpreting
results of a microarray, wherein the tool is a
computer program for
analyzing the results of microrarrays. A
method of creating an array of
markers for diagnosing the presence of
disease by microarraying sera
obtained from a patient to obtain molecular
markers of disease and
detecting markers that are present only in the
sera of patients with a
specific disease thereby detecting molecular
markers being used to
determine gene expression changes that are
related to cellular
immortalization and for use in diagnosing
disease.

CAS INDEXING IS AVAILABLE FOR THIS
PATENT.

L4 ANSWER 3 OF 9 MEDLINE on STN
DUPLICATE 1

ACCESSION NUMBER: 2005259425
 MEDLINE
 DOCUMENT NUMBER: PubMed ID:
 15899864
 TITLE: Mice deficient in oocyte-specific
 oligoadenylate
 synthetase-like protein OAS1D
 display reduced fertility.
 AUTHOR: Yan Wei; Ma Lang; Stein
 Paula; Pangas Stephanie A; Burns
 Kathleen H; Bai Yuchen; Schultz
 Richard M; Matzuk Martin M
 CORPORATE SOURCE: Department of
 Pathology, Baylor College of Medicine, One
 Baylor Plaza, Houston, TX 77030,
 USA.
 CONTRACT NUMBER: F32 HD046335-
 01A1 (NICHD)
 GM07330 (NIGMS)
 HD007165 (NICHD)
 HD22681 (NICHD)
 HD42500 (NICHD)
 SOURCE: Molecular and cellular
 biology, (2005 Jun) Vol. 25, No. 11,
 pp. 4615-24.
 Journal code: 8109087. ISSN: 0270-
 7306.
 PUB. COUNTRY: United States
 DOCUMENT TYPE: Journal; Article;
 (JOURNAL ARTICLE)
 LANGUAGE: English
 FILE SEGMENT: Priority Journals
 ENTRY MONTH: 200507
 ENTRY DATE: Entered STN: 19 May
 2005
 Last Updated on STN: 22 Jul 2005
 Entered Medline: 21 Jul 2005
 AB The double-stranded RNA (dsRNA)-
 induced interferon response is a defense
 mechanism against viral infection. Upon
 interferon activation by dsRNA,
 2',5'-oligoadenylate synthetase 1 (OAS1A) is
 induced; it binds dsRNA and
 converts ATP into 2',5'-linked oligomers of
 adenosine (called 2-5A), which
 activate RNase L that in turn degrades viral
 and cellular RNAs. In a
 screen to identify oocyte-specific genes, we
 identified a novel murine
 cDNA encoding an ovary-specific 2',5'-
 oligoadenylate synthetase-like
 protein, OAS1D, which displays 59% identity
 with OAS1A. OAS1D is
 predominantly cytoplasmic and is exclusively
 expressed in growing oocytes

and early embryos. Like OAS1A, OAS1D
 binds the dsRNA mimetic poly(I-C),
 but unlike OAS1A, it lacks 2'-5' adenosine
 linking activity. OAS1D
 interacts with OAS1A and inhibits the
 enzymatic activity of OAS1A. Mutant
 mice lacking OAS1D (Oas1d^{-/-}) display
 reduced fertility due to defects
 in ovarian follicle development, decreased
 efficiency of ovulation, and
 eggs that are fertilized arrest at the one-cell
 stage. These effects are
 exacerbated after activation of the
 interferon/OAS1A/RNase L pathway by
 poly(I-C). We propose that OAS1D
 suppresses the interferon/
 OAS/RNase L-mediated cellular destruction
 by interacting with
 OAS1A during oogenesis and early
 embryonic development.

L4 ANSWER 4 OF 9 BIOSIS COPYRIGHT
 (c) 2006 The Thomson Corporation on STN
 ACCESSION NUMBER: 2005:104488
 BIOSIS

DOCUMENT NUMBER:
 PREV200500103216
 TITLE: Combination immunotherapy
 with a CpG oligonucleotide (1018
 ISS) and rituximab in patients with
 non-Hodgkin lymphoma:
 increased interferon-alpha/beta-
 inducible gene expression,
 without significant toxicity.
 AUTHOR(S): Friedberg, Jonathan W.
 [Reprint Author]; Kim, Helen;
 McCauley, Mary; Hessel, Edith M.;
 Sims, Paul; Fisher, David
 C.; Nadler, Lee M.; Coffman,
 Robert L.; Freedman, Arnold S.
 CORPORATE SOURCE: Lymphoma
 Program James P Wilmot Canc Ctr, Univ
 Rochester,
 601 Elmwood Ave, Box 704,
 Rochester, NY, 14642, USA

jonathan_friedberg@urmc.rochester.edu
 SOURCE: Blood, (January 15 2005) Vol.
 105, No. 2, pp. 489-495.
 print.
 CODEN: BLOOAW. ISSN: 0006-
 4971.

DOCUMENT TYPE: Article
 LANGUAGE: English
 ENTRY DATE: Entered STN: 16 Mar 2005
 Last Updated on STN: 16 Mar 2005